The purpose of this article is to report a case of severe stomatitis in a patient with pediatric epilepsy taking divalproex sodium. The case was reviewed with detailed oral examinations. This 5-year-old child developed severe stomatitis 18 months after institution of divalproex sodium. Cessation of the medication was associated with resolution of the stomatitis. A review of the pertinent literature is also provided. Stomatitis is a rare but potentially serious adverse effect of divalproex sodium administration. (J Child Neurol 2002;17: 225-227).
Kennett S.: Erythema multiforme affecting the oral cavity. Oral Surg Oral Med Oral Pathol1968;25:366-373.
3.
Roujeau JC, Kelly JP, Naldi L., et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med1995;333:1600-1607.
4.
Rzany B., Correia O., Kelly JP, et al: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study. Lancet1999;353:2190-2194.
Sachs B., Ronnau AC, von Schmiedeberg S., et al: Lamotrigine-induced Stevens-Johnson syndrome: Demonstration of specific lymphocyte reactivity in vivo. Dermatology1997;195:60-64.
7.
Schlienger RG , Shapiro LE, Shear NH: Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia1998;39(Suppl 7):S22-S26.
8.
Page RL2nd, O'Neil MG, Yarbrough DR 3rd, Conradi S: Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy1998;18:392-398.
9.
Messenheimer J., Mullens EL, Giorgi L., Young F.: Safety review of adult clinical trial experience with lamotrigine. Drug Saf1998;18: 281-296.
10.
Depakote product information. North Chicago, IL, Abbott Laboratories, 1998.
11.
Gallagher GT : Oral mucous membrane reactions to drugs and chemicals. Curr OpinDent1991;1:777-782.
